|Samir Chachoua (HIV VACCINE)
Jul 23, 2008
dr. bob please watch this- do you know this guy???? (Submitted Jul 16, 2008)
This is some youtube posting of the lost cure for cancer and hiv. Please tell me what you think about it.
Thank you. Sebby
Hi Dr. Bob,
Its Sebby again. I sent you that link about the lost cure for hiv/cancer/aids- the youtube link. Even if this true or not- there is one interesting point- Samir claims that the human body cant see cancer or hiv/aids- but he claimed that the human body can see the flu virus- so if in the vaccine he developed you attach particles of hiv/aids to the flu virus - you can actually benefit the body and cause a positive body reaction against hiv. Is there any truth to this at all. Please advise. Sebby
| Response from Dr. Frascino
Many people send me links to "lost cures for HIV/cancer/AIDS." If I were to comment about them all, I wouldn't be able to answer so many other questions, like the closeted rightwing GOP congressman who gets off on barely legal prostitutes with webbed feet and a penchant for narcolepsy. At any rate, the "lost cure" you referenced is just as phony as all the rest. There is no cure for HIV/AIDS. If one existed, don't you think I'd be standing in line waiting for my fix? And common sense would dictate that a cure for AIDS would be headline news, not only located on an obscure YouTube link! The HIV/AIDS vaccine story continues to be one of profound disappointment. Another major clinical trial was canceled this week. (See below.)
Trial for Vaccine Against H.I.V. Is Canceled
By LAWRENCE K. ALTMAN Published: July 18, 2008
Plans for a large human trial of a promising government-developed H.I.V. vaccine in the United States were canceled Thursday because a top federal official said scientists realized that they did not know enough about how H.I.V. vaccines and the immune system interact. The decision is a major setback in an effort to develop an H.I.V. vaccine that began 24 years ago when government health officials promised a marketed vaccine by 1987. Health officials have long contended that such a vaccine would be their best weapon to control the AIDS pandemic.
A number of other H.I.V. vaccines are in various stages of testing around the world. But there had been high hopes for the government's trial because the potential vaccine was among a new class that sought to stimulate the immune system in a different way. The official who canceled the government trial, Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, said it was becoming clearer that more fundamental research and animal testing would be needed before an H.I.V. vaccine was ever marketed.
Scientists say that developing a vaccine against H.I.V. is one of the most difficult scientific endeavors in history because of the uncanny nature of the virus.
The government vaccine known as PAVE, for Partnership for AIDS Vaccine Evaluation was similar to a much-heralded vaccine that failed last year. That vaccine was developed by Merck, and Dr. Fauci's agency helped pay for the Merck trials.
Dr. Fauci said he reached his decision to cancel the coming trial after meeting with scientists to try to understand why the Merck vaccine had failed. He said he had concluded that scientists must go a step at a time because they did not yet know fundamental facts like which immune reactions are the most important in preventing the infection.
Dr. Fauci said the new trial was intended to determine whether the vaccine could significantly lower the amount of H.I.V. in the blood of those who become infected. He said a smaller trial was needed to figure out whether the vaccine could do that before large trials were conducted.
"Show me that the vaccine works by lowering the amount of H.I.V. in the blood," Dr. Fauci said. "Then we will move to a larger trial that will document the link with a particular immune response." He added that until then, "doing a large trial is not justified." Dr. Alan Bernstein, executive director of the Global HIV Vaccine Enterprise, said that his organization supported Dr. Fauci's decision and that there was an "urgent need for a diversity of new approaches to H.I.V. vaccine design."
For instance, Dr. Bernstein said, recent laboratory advances, which allow scientists to look at hundreds of genes simultaneously, "offer immense promise in helping us understand how to design new H.I.V. vaccine candidates that can achieve long-lasting immune protection." The trial canceled Thursday was supposed to have started enrolling 8,500 volunteers last October to receive the PAVE vaccine, developed by the infectious diseases agency. PAVE is a consortium of federal agencies and key federally financed organizations involved in developing and evaluating experimental H.I.V. vaccines. It seeks to create an effective H.I.V. vaccine that no pharmaceutical company or institution is likely to accomplish on its own.
The PAVE trial had been postponed after a test of the Merck vaccine failed in its two main objectives: to prevent infection and to lower the amount of H.I.V. in the blood among those who became infected. Also, the findings among the 3,000 participants in nine countries in which the Merck vaccine was tested suggested it might have increased the risk of becoming infected.
After a safety monitoring committee detected the problems with the Merck vaccine in September, the company quickly halted its study. Scientists have found no obvious explanation for the failure of the Merck vaccine, which had been considered the most promising candidate.
The Merck vaccine was the first of a new class of H.I.V. vaccines to get to an advanced stage in human testing. The vaccine was made from a weakened version of a common cold virus, adenovirus type 5, which served as a way to deliver three synthetically produced genes gag, pol and nef from the AIDS virus. Three doses of the vaccine were injected over six months.
Scientific analyses found that the highest risk of H.I.V. infection among recipients of the Merck vaccine was in males who both were uncircumcised and had pre-existing antibodies to adenovirus type 5. After the failure of Merck trial, the government reduced the number of potential volunteers to 2,400; they would have included circumcised gay men who had no pre-existing antibodies to adenovirus type 5. The scaled-back study would have cost about $63 million, compared with $140 million for the initial design.
At a news conference in 1984, top federal officials said they were optimistic that a marketable H.I.V. vaccine would be available in three years. Since then, AIDS researchers have been divided about how fast to test experimental vaccines.
Many urge caution out of fear that failures could destroy confidence among uninfected people most at risk who would be needed as volunteers in future trials.
But equally vocal groups call for testing everything as soon as the research shows promise because of the urgent need for a vaccine. In an unrelated development, researchers at Duke University reported new findings Thursday showing that H.I.V. stuns the immune system earlier than scientists previously understood.
The window of opportunity in stopping H.I.V. may be a matter concerning the first few days, not weeks, after the virus enters the body, a team headed by Dr. Barton Haynes reported in The Journal of Virology.
The findings were based on a study of 30 individuals newly infected with H.I.V., and the National Institutes of Health paid for the study.
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.